Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$11.33 +8.2%	$10.42	$7.80 ▼ $28.09	$617.94M	N/A	610,975 shs	275,938 shs
ORGO Organogenesis	$4.91 +0.4%	$4.10	$2.45 ▼ $6.71	$622.87M	1.76	1.47 million shs	592,498 shs
TRML Tourmaline Bio	$22.22 +3.4%	$18.84	$11.56 ▼ $29.79	$570.61M	2.04	293,989 shs	206,462 shs
VCXB 10X Capital Venture Acquisition Corp. III	$11.07	$11.05	$10.48 ▼ $12.99	$146.01M	0.07	43,760 shs	16,992 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+4.80%	-7.83%	+7.83%	-23.58%	+1,046,999,900.00%
ORGO Organogenesis	+6.07%	+7.95%	+13.72%	+62.46%	+102.07%
TRML Tourmaline Bio	+2.33%	-4.19%	+19.47%	+38.58%	+52.88%
VCXB 10X Capital Venture Acquisition Corp. III	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	4.3679 of 5 stars	3.3	2.0	0.0	4.3	2.3	4.2	0.6
TRML Tourmaline Bio	1.9288 of 5 stars	3.5	0.0	0.0	0.0	3.3	2.5	0.0
VCXB 10X Capital Venture Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	181.19% Upside
ORGO Organogenesis	2.67	Moderate Buy	$7.50	52.75% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	122.02% Upside
VCXB 10X Capital Venture Acquisition Corp. III	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VCXB, ORGO, BCAX, and TRML Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
8/8/2025	ORGO Organogenesis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.00 ➝ $9.00
7/15/2025	ORGO Organogenesis	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/15/2025	ORGO Organogenesis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
ORGO Organogenesis	$429.31M	1.45	$0.22 per share	22.12	$1.84 per share	2.67
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A
VCXB 10X Capital Venture Acquisition Corp. III	N/A	N/A	$0.06 per share	176.88	($1.49) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	$860K	-$0.14	N/A	N/A	N/A	-1.92%	-0.37%	-0.20%	N/A
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/14/2025 (Estimated)
VCXB 10X Capital Venture Acquisition Corp. III	$700K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VCXB, ORGO, BCAX, and TRML Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TRML Tourmaline Bio	-$0.95	-$0.90	+$0.05	-$0.90	N/A	N/A
8/12/2025	Q2 2025	BCAX Bicara Therapeutics	-$0.54	-$0.50	+$0.04	-$0.50	N/A	N/A
8/7/2025	Q2 2025	ORGO Organogenesis	-$0.01	-$0.09	-$0.08	-$0.10	$104.75 million	$101.01 million
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A
VCXB 10X Capital Venture Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	24.62	24.62
ORGO Organogenesis	N/A	3.95	3.45
TRML Tourmaline Bio	N/A	33.87	33.87
VCXB 10X Capital Venture Acquisition Corp. III	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
ORGO Organogenesis	49.57%
TRML Tourmaline Bio	91.89%
VCXB 10X Capital Venture Acquisition Corp. III	13.25%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	N/A
ORGO Organogenesis	33.00%
TRML Tourmaline Bio	13.00%
VCXB 10X Capital Venture Acquisition Corp. III	82.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
ORGO Organogenesis	950	126.86 million	85.00 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable
VCXB 10X Capital Venture Acquisition Corp. III	4	13.19 million	2.31 million	Not Optionable

VCXB, ORGO, BCAX, and TRML Headlines

Recent News About These Companies

10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing

April 23, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VCXB, ORGO, BCAX, and TRML Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$11.33 +0.86 (+8.21%)

Closing price 04:00 PM Eastern

Extended Trading

$11.32 -0.02 (-0.13%)

As of 05:32 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Organogenesis NASDAQ:ORGO

$4.91 +0.02 (+0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$4.90 -0.01 (-0.20%)

As of 04:20 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Tourmaline Bio NASDAQ:TRML

$22.22 +0.74 (+3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$22.24 +0.02 (+0.09%)

As of 07:47 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

10X Capital Venture Acquisition Corp. III NYSE:VCXB

10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York. 10X Capital Venture Acquisition Corp. III operates as a subsidiary of 10X Capital SPAC Sponsor III LLC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time